Behavioral Activation for Depression

Phase-Based Progress Estimates
Massachusetts General Hospital, Boston, MA
Depression+1 More
Online- BA - Behavioral
All Sexes
What conditions do you have?

Study Summary

This is a parallel group study design. The investigators propose to compare an online, synchronous group-based yoga intervention developed for individuals with depression to an online, synchronous individualized, evidence-based behavioral therapy for depression, or Brief Behavioral Activation Treatment for Depression (BA). This study is a multi-site randomized trial of adults with clinically significant depressive symptoms. Participants (N=518) will be randomized in an equal allocation ratio (i.e., 1:1) across two intervention groups: yoga and BA. Interventions will be provided over a 12-week period and assessments will occur at baseline (week 0), week 6, week 12, week 18, and week 24.

Eligible Conditions

  • Depression

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Depression

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Week: 0, 6, 12, 18, 24

Week: 0, 6, 12, 18, 24
World Health Organization-5 Well-Being Index (WHO-5)
Week: 24
Patient Health Questionnaire-9 (PHQ-9)

Trial Safety

Safety Progress

1 of 3

Other trials for Depression

Trial Design

2 Treatment Groups

Behavioral Activation
1 of 2
Yoga-based Intervention
1 of 2
Active Control

518 Total Participants · 2 Treatment Groups

Primary Treatment: Behavioral Activation · No Placebo Group · N/A

Behavioral Activation
ActiveComparator Group · 1 Intervention: Online- BA · Intervention Types: Behavioral
Yoga-based Intervention
ActiveComparator Group · 1 Intervention: Online- Yoga-based Intervetion · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week: 0, 6, 12, 18, 24
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital 1Photo of Massachusetts General Hospital 2Photo of Massachusetts General Hospital 3
1993First Recorded Clinical Trial
108 TrialsResearching Depression
2430 CompletedClinical Trials

Who is running the clinical trial?

Butler HospitalOTHER
117 Previous Clinical Trials
12,349 Total Patients Enrolled
27 Trials studying Depression
2,631 Patients Enrolled for Depression
Wake Forest University Health SciencesOTHER
1,100 Previous Clinical Trials
1,128,507 Total Patients Enrolled
27 Trials studying Depression
30,911 Patients Enrolled for Depression
Brown UniversityOTHER
406 Previous Clinical Trials
514,663 Total Patients Enrolled
28 Trials studying Depression
10,655 Patients Enrolled for Depression
Massachusetts General HospitalLead Sponsor
2,660 Previous Clinical Trials
30,828,279 Total Patients Enrolled
171 Trials studying Depression
29,080 Patients Enrolled for Depression
Hennepin Healthcare Research InstituteOTHER
83 Previous Clinical Trials
3,663,046 Total Patients Enrolled
2 Trials studying Depression
19,122 Patients Enrolled for Depression
Medical University of South CarolinaOTHER
828 Previous Clinical Trials
5,371,335 Total Patients Enrolled
35 Trials studying Depression
6,199 Patients Enrolled for Depression
Louisa Sylvia, PhDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
24 Total Patients Enrolled
1 Trials studying Depression
24 Patients Enrolled for Depression
Lisa Uebelacker, PhDPrincipal InvestigatorButler Hospital
8 Previous Clinical Trials
442 Total Patients Enrolled
5 Trials studying Depression
351 Patients Enrolled for Depression

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be aged 18 years old or older.
You have symptoms of depression.
You live in the states of Massachusetts, Minnesota, or Rhode Island.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.